LT3525583T - Anti-c1s antikūnai ir jų naudojimo būdai - Google Patents

Anti-c1s antikūnai ir jų naudojimo būdai

Info

Publication number
LT3525583T
LT3525583T LTEPPCT/US2017/056349T LTUS2017056349T LT3525583T LT 3525583 T LT3525583 T LT 3525583T LT US2017056349 T LTUS2017056349 T LT US2017056349T LT 3525583 T LT3525583 T LT 3525583T
Authority
LT
Lithuania
Prior art keywords
antibodies
methods
Prior art date
Application number
LTEPPCT/US2017/056349T
Other languages
English (en)
Lithuanian (lt)
Inventor
Sandip PANICKER
Graham Parry
Nancy Stagliano
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of LT3525583T publication Critical patent/LT3525583T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
LTEPPCT/US2017/056349T 2016-10-12 2017-10-12 Anti-c1s antikūnai ir jų naudojimo būdai LT3525583T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662407390P 2016-10-12 2016-10-12
PCT/US2017/056349 WO2018071676A1 (en) 2016-10-12 2017-10-12 Anti-c1s antibodies and methods of use thereof

Publications (1)

Publication Number Publication Date
LT3525583T true LT3525583T (lt) 2025-11-10

Family

ID=61906346

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/US2017/056349T LT3525583T (lt) 2016-10-12 2017-10-12 Anti-c1s antikūnai ir jų naudojimo būdai

Country Status (35)

Country Link
US (3) US20200048332A1 (cg-RX-API-DMAC10.html)
EP (2) EP4652926A3 (cg-RX-API-DMAC10.html)
JP (3) JP7069138B2 (cg-RX-API-DMAC10.html)
KR (3) KR102891406B1 (cg-RX-API-DMAC10.html)
CN (2) CN110300520B (cg-RX-API-DMAC10.html)
AR (1) AR110677A1 (cg-RX-API-DMAC10.html)
AU (3) AU2017341766A1 (cg-RX-API-DMAC10.html)
BR (1) BR112019007309A2 (cg-RX-API-DMAC10.html)
CA (1) CA3040253A1 (cg-RX-API-DMAC10.html)
CL (1) CL2019000975A1 (cg-RX-API-DMAC10.html)
CO (1) CO2019004741A2 (cg-RX-API-DMAC10.html)
CR (1) CR20190223A (cg-RX-API-DMAC10.html)
DK (1) DK3525583T3 (cg-RX-API-DMAC10.html)
DO (1) DOP2019000085A (cg-RX-API-DMAC10.html)
EA (1) EA201990884A1 (cg-RX-API-DMAC10.html)
EC (1) ECSP19033211A (cg-RX-API-DMAC10.html)
ES (1) ES3049257T3 (cg-RX-API-DMAC10.html)
FI (1) FI3525583T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20251304T1 (cg-RX-API-DMAC10.html)
HU (1) HUE073475T2 (cg-RX-API-DMAC10.html)
IL (3) IL326479A (cg-RX-API-DMAC10.html)
LT (1) LT3525583T (cg-RX-API-DMAC10.html)
MX (2) MX2019004259A (cg-RX-API-DMAC10.html)
MY (1) MY198182A (cg-RX-API-DMAC10.html)
PE (1) PE20191031A1 (cg-RX-API-DMAC10.html)
PH (1) PH12019500789A1 (cg-RX-API-DMAC10.html)
PL (1) PL3525583T3 (cg-RX-API-DMAC10.html)
PT (1) PT3525583T (cg-RX-API-DMAC10.html)
RS (1) RS67326B1 (cg-RX-API-DMAC10.html)
SG (1) SG11201903012RA (cg-RX-API-DMAC10.html)
SI (1) SI3525583T1 (cg-RX-API-DMAC10.html)
TN (1) TN2019000109A1 (cg-RX-API-DMAC10.html)
TW (3) TWI773695B (cg-RX-API-DMAC10.html)
WO (1) WO2018071676A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201902247B (cg-RX-API-DMAC10.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014066744A2 (en) 2012-10-25 2014-05-01 True North Therapeutics, Inc. Anti-complement c1s antibodies and uses thereof
ES2912396T3 (es) 2012-11-02 2022-05-25 Bioverativ Usa Inc Anticuerpos anti-C1s del complemento y uso de los mismos
EP4212175A1 (en) 2015-04-06 2023-07-19 Bioverativ USA Inc. Humanized anti-c1s antibodies and methods of use thereof
IL326479A (en) * 2016-10-12 2026-04-01 Bioverativ Usa Inc Anti-c1s antibodies and methods of use thereof
EP4640703A3 (en) 2017-11-14 2026-04-08 Chugai Seiyaku Kabushiki Kaisha Anti-c1s antibodies and methods of use
CA3137649A1 (en) 2019-05-15 2020-11-19 Chugai Seiyaku Kabushiki Kaisha An antigen-binding molecule, a pharmaceutical composition, and a method
TWI900560B (zh) * 2020-04-20 2025-10-11 美商健臻公司 人類化抗補體因子bb抗體及其用途
KR20230013037A (ko) * 2020-04-22 2023-01-26 키모맙 엘티디. 항-ccl24 항체를 이용한 치료 방법
CN115551519A (zh) * 2020-05-11 2022-12-30 基因泰克公司 用于治疗神经系统疾病的补体组分c1s抑制剂以及相关的组合物、系统和使用它们的方法
BR112023001942A2 (pt) * 2020-08-06 2023-02-28 Bioverativ Usa Inc Citocinas inflamatórias e fadiga em indivíduo com doença mediada por complemento
CA3155939A1 (en) * 2021-04-30 2022-10-30 Upm-Kymmene Corporation A method for freeze-drying a hydrogel composition and a freeze-dried hydrogel composition
US12252550B2 (en) 2021-05-20 2025-03-18 Dianthus Therapeutics Opco, Inc. Antibodies that bind to C1S and uses thereof
CN117642431B (zh) * 2021-07-13 2025-07-15 迈威(美国)生物治疗有限公司 抗c1s抗体和其用途
IL317666A (en) 2022-06-15 2025-02-01 Bioverativ Usa Inc Anti-complement formulation for C1S antibody
MA71249A (fr) 2022-06-24 2025-04-30 Bioverativ Usa Inc. Méthodes de traitement de maladies médiées par complément
TW202426490A (zh) 2022-11-21 2024-07-01 美商黛安瑟斯醫療運營公司 結合ｃ１ｓ之抗體及其用途
KR20250158063A (ko) 2023-03-16 2025-11-05 젠자임 코포레이션 건식 연령-관련 황반 변성의 치료

Family Cites Families (143)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS60192263A (ja) 1984-03-13 1985-09-30 Teijin Ltd 免疫複合体測定用標準物質及びそれを用いた免疫複合体の測定法
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
CA1276103C (en) 1984-10-02 1990-11-13 Fumiaki Taguchi Substance-conjugated complement component c1q
JPS61271455A (ja) 1985-05-28 1986-12-01 Olympus Optical Co Ltd 免疫学的分析方法
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JPH02500329A (ja) 1987-05-21 1990-02-08 クリエイテイブ・バイオマリキユールズ・インコーポレーテツド ターゲット化多機能蛋白質
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
ATE237694T1 (de) 1991-08-20 2003-05-15 Us Gov Health & Human Serv Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
JP3540315B2 (ja) 1991-09-23 2004-07-07 メディカル リサーチ カウンシル キメラ抗体の製造−組合せアプローチ
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
EP0673431A1 (en) 1992-12-03 1995-09-27 Genzyme Corporation Gene therapy for cystic fibrosis
DE614989T1 (de) 1993-02-17 1995-09-28 Morphosys Proteinoptimierung Verfahren für in vivo Selektion von Ligandenbindende Proteine.
EP0705344B8 (en) 1993-06-24 2006-05-10 Advec Inc. Adenovirus vectors for gene therapy
EP0716611B1 (en) 1993-09-01 2002-02-06 Stichting Sanquin Bloedvoorziening C1-esterase inhibitor to reduce myocardial injury during acute myocardial infarction
DE69435223D1 (de) 1993-10-25 2009-09-03 Canji Inc Rekombinanter Adenoviren-Vektor und Verfahren zur Verwendung
SG119177A1 (en) 1994-12-09 2006-02-28 Imp College Innovations Ltd Identification of genes
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5968511A (en) 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
PT904392E (pt) 1996-10-17 2001-06-29 Oxford Biomedica Ltd Vectores retrovirais
GB9621680D0 (en) 1996-10-17 1996-12-11 Oxford Biomedica Ltd Lentiviral vectors
GB9622500D0 (en) 1996-10-29 1997-01-08 Oxford Biomedica Ltd Therapeutic gene
US6969601B2 (en) 1997-04-03 2005-11-29 Jensenius Jens Chr MASP-2, a complement-fixing enzyme, and uses for it
US6080849A (en) 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
EP3056516A1 (en) 1998-02-20 2016-08-17 Genentech, Inc. Inhibitors of complement activation
US6103526A (en) 1998-10-08 2000-08-15 Protein Sciences Corporation Spodoptera frugiperda single cell suspension cell line in serum-free media, methods of producing and using
EP1152759A2 (en) 1999-02-09 2001-11-14 3-Dimensional Pharmaceuticals, Inc. METHODS OF TREATING C1s-MEDIATED DISEASES AND CONDITIONS, AND COMPOUNDS AND COMPOSITIONS THEREFOR
AU4369000A (en) 1999-04-26 2000-11-10 Duke University Inhibition of complement action
WO2001013945A1 (en) 1999-08-23 2001-03-01 Biocrystal Ltd. Methods and compositions for immunotherapy of b cell involvement in promotion of a disease condition comprising multiple sclerosis
EP1250594A4 (en) 2000-01-19 2003-05-07 Biotransplant Inc PORC UNABLE TO TRANSMIT PORCINE ENDOGENEOUS RETROVIRUS, AND USES THEREOF
EP1252184B1 (en) 2000-01-31 2008-01-02 Pharming Intellectual Property B.V. Human c1 inhibitor produced in the milk of transgenic mammals
US6998468B2 (en) 2000-03-23 2006-02-14 Tanox, Inc. Anti-C2/C2a inhibitors of complement activation
EP1349874A2 (en) 2000-06-21 2003-10-08 ZymoGenetics, Inc. Peptide and polypeptide inhibitors of complement c1s
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
GB0105924D0 (en) 2001-03-09 2001-04-25 Microscience Ltd Promoter
EP1416962A4 (en) 2001-07-26 2006-05-24 Alexion Pharma Inc METHOD FOR IMPROVING THE COGNITIVE FUNCTION
EP1572893B1 (en) 2001-11-09 2009-01-07 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY of the DEPARTMENT OF HEALTH AND HUMAN SERVICES Production of adeno-associated virus in insect cells
JP2005515782A (ja) 2002-01-11 2005-06-02 ジーティーシー バイオセラピューティックス インコーポレイテッド 再構築された胚へ核を移植した後の融合および活性化のための方法およびシステム
US20080206242A1 (en) 2002-03-01 2008-08-28 Xencor, Inc. Method of treatment of th2-mediated conditions using optimized anti-cd30 antibodies
SE0202880D0 (sv) 2002-07-26 2002-09-30 Wieslab Ab Complement system deficiency assay
US7666627B2 (en) 2002-08-08 2010-02-23 Targetex Kft. Folded recombinant catalytic fragments of multidomain serine proteases, preparation and uses thereof
EP1545611B1 (en) 2002-09-06 2016-11-09 Alexion Pharmaceuticals, Inc. Method of treatment of asthma using antibodies to complement component c5
US20050271660A1 (en) 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
US7361339B2 (en) 2003-01-09 2008-04-22 Alexion Pharmaceuticals, Inc. Methods for reducing morality associated with acute myocardial infarction
US9715692B1 (en) 2003-04-11 2017-07-25 Facebook, Inc. System for managing bids for pay-per-click search engines
EP2266606B1 (en) 2003-05-15 2014-09-10 Genentech, Inc. Methods and compositions for the prevention and treatment of sepsis
WO2005014849A2 (en) 2003-07-03 2005-02-17 Euro-Celtique, S.A. Genes associated with responses to neuropathic pain
US7482376B2 (en) 2003-07-03 2009-01-27 3-Dimensional Pharmaceuticals, Inc. Conjugated complement cascade inhibitors
WO2005025509A2 (en) 2003-09-11 2005-03-24 Board Of Regents, The University Of Texas System Methods and materials for treating autoimmune diseases and conditions
US8501705B2 (en) 2003-09-11 2013-08-06 The Board Of Regents Of The University Of Texas System Methods and materials for treating autoimmune and/or complement mediated diseases and conditions
AU2003271186A1 (en) 2003-10-14 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
JP2007512846A (ja) 2003-12-04 2007-05-24 ゼンコー・インコーポレイテッド 増加した宿主ストリング含有量を有する変異体タンパク質の生成方法およびその組成物
US7803931B2 (en) 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
WO2005100402A1 (en) * 2004-04-13 2005-10-27 F.Hoffmann-La Roche Ag Anti-p-selectin antibodies
US20060018896A1 (en) 2004-06-10 2006-01-26 University Of Leicester Methods for treating conditions associated with lectin-dependent complement activation
EP2465534B1 (en) 2004-06-10 2017-03-29 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US7919094B2 (en) 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US8367805B2 (en) * 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US9200079B2 (en) 2004-11-12 2015-12-01 Xencor, Inc. Fc variants with altered binding to FcRn
US8420783B2 (en) 2004-12-08 2013-04-16 Immunomedics, Inc. Method and compositions for immunotherapy of inflammatory and immune-dysregulatory diseases
DE602006010834D1 (de) 2005-03-16 2010-01-14 Janssen Pharmaceutica Nv Neue thiophensulfoximine zur behandlung von komplementvermittelten krankheiten und leiden
WO2006130834A2 (en) 2005-05-31 2006-12-07 Board Of Regents, The University Of Texas System IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF
EP1893227A2 (en) 2005-06-06 2008-03-05 Girish J. Kotwal Methods for treatment or prophylaxis of atherosclerosis and reperfusion injury
EP1908797B1 (en) 2005-07-05 2012-06-06 Kaneka Corporation Methacrylic resin composition
CA2619725C (en) 2005-08-18 2016-06-07 Ramot At Tel Aviv University Ltd. Single chain antibodies against beta-amyloid peptide
KR101126423B1 (ko) 2005-10-21 2012-07-11 카탈리스트 바이오사이언시즈, 인코포레이티드 보체 활성화를 억제하는 변형된 프로테아제
US9480658B2 (en) 2005-12-09 2016-11-01 The Board Of Trustees Of The Leland Stanford Junior University Modulation of synaptic maintenance
US8148330B2 (en) 2005-12-09 2012-04-03 The Board Of Trustees Of The Leland Stanford Junior University Modulation of synaptic maintenance
US8071532B2 (en) 2005-12-21 2011-12-06 Pharming Intellectual Property B.V. Use of C1 inhibitor for the prevention of ischemia-reperfusion injury
FR2897868B1 (fr) * 2006-02-24 2012-08-31 Lab Francais Du Fractionnement Anticorps anti-idiotypiques neutralisant l'activite inhibitrice d'un anticorps inhibiteur dirige contre le domaine c1 du facteur viii.
DK1991275T3 (en) 2006-03-08 2014-12-08 Archemix Llc Complement aptamers AND ANTI-C5 AGENTS FOR USE IN THE TREATMENT OF EYE DISEASES
AR060040A1 (es) 2006-03-21 2008-05-21 Genentech Inc Antagonistas de vefg y de alfa5 beta 1
WO2007148971A2 (en) 2006-06-21 2007-12-27 Amsterdam Molecular Therapeutics B.V. Vectors with modified initiation codon for the translation of aav-rep78 useful for production of aav in insect cells
WO2008030505A2 (en) 2006-09-05 2008-03-13 Alexion Pharmaceuticals, Inc. Methods and compositions for the treatment of antibody mediated neuropathies
LT3028716T (lt) 2006-10-10 2020-12-10 Regenesance B.V. Komplemento slopinimas nervų regeneracijos pagerinimui
US7858752B2 (en) 2006-12-05 2010-12-28 Abbott Laboratories Recombinant antibodies against hepatitis C virus and methods of obtaining and using same
TW200844079A (en) 2006-12-19 2008-11-16 Versitech Ltd Synthetic ion channels
EP2148691B1 (en) 2007-02-05 2015-05-20 Apellis Pharmaceuticals, Inc. Compstatin analogues for use in the treatment of inflammatory conditions of the respiratory system
US8192742B2 (en) 2007-03-23 2012-06-05 NovelMed Therapeutics Method of inhibiting complement activation with human anti-factor C3 antibodies and use thereof
PT2474557E (pt) 2007-07-16 2014-12-03 Genentech Inc Anticorpos e imunoconjugados anti-cd79b e métodos de utilização
EP2188310B1 (en) 2007-08-03 2017-02-08 Genentech, Inc. Humanized anti-fgf19 antagonists and methods using same
US7788398B2 (en) * 2007-08-08 2010-08-31 Swarmcast, Inc. Media player plug-in installation techniques
KR101616758B1 (ko) 2007-12-26 2016-04-29 젠코어 인코포레이티드 ＦｃＲｎ에 대한 변경된 결합성을 갖는 Ｆｃ 변이체
WO2009121065A2 (en) 2008-03-28 2009-10-01 Apellis Ag Modulation and repletion/enhancement of the complement system for treatment of trauma
CA2720682A1 (en) 2008-04-25 2009-10-29 Zymogenetics, Inc. Levels of bcma protein expression on b cells and use in diagnostic methods
WO2010033279A2 (en) 2008-06-04 2010-03-25 Macrogenics, Inc. Antibodies with altered binding to fcrn and methods of using same
WO2009151634A1 (en) 2008-06-12 2009-12-17 The Board Of Trustees Of The Leland Stanford Junior University Complement inhibitory agents as therapeutics in posttraumatic and degenerative arthritis
PY09026846A (es) 2008-08-05 2015-09-01 Novartis Ag Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
US20110311550A1 (en) 2008-10-24 2011-12-22 The Scripps Research Institute Agents for hcv treatment
JP6223659B2 (ja) 2008-11-10 2017-11-01 アレクシオン ファーマシューティカルズ， インコーポレイテッド 補体関連障害を処置するための方法および組成物
AU2009322607B2 (en) 2008-12-01 2015-05-14 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for detection of complement fixing antibodies
CA2745439C (en) * 2008-12-03 2019-10-15 Genmab A/S Antibody variants having modifications in the constant region
US8401799B2 (en) 2008-12-05 2013-03-19 Lpath, Inc. Antibody design using anti-lipid antibody crystal structures
US20100291106A1 (en) 2009-05-06 2010-11-18 Novartis Ag Compositions and methods for antibodies targeting complement protein c3b
US8734809B2 (en) 2009-05-28 2014-05-27 University Of Massachusetts AAV's and uses thereof
NZ597259A (en) 2009-06-23 2014-04-30 Alexion Pharma Inc Bispecific antibodies that bind to complement proteins
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
EP3150635A3 (en) 2009-10-16 2017-06-21 Omeros Corporation Methods for treating disseminated intravascular coagulation by inhibiting masp-2 dependent complement activation
US8883985B2 (en) 2010-02-16 2014-11-11 National University Corporation Kyoto Institute Of Technology Antibody-immobilized carrier, method of producing antibody-immobilized carrier, and use of said antibody-immobilized carrier
WO2011109338A1 (en) 2010-03-01 2011-09-09 Alexion Pharmaceuticals Inc. Methods and compositions for treating degos' disease
DK2561073T3 (en) 2010-04-23 2016-12-12 Univ Massachusetts Aav vectors targeted to central nervous system and methods of use thereof
AU2011245117B2 (en) 2010-04-30 2015-03-12 Alexion Pharmaceuticals, Inc. Anti-C5a antibodies and methods for using the antibodies
CA2799746C (en) 2010-05-17 2020-11-24 Sai Reddy Rapid isolation of monoclonal antibodies from animals
US9421240B2 (en) 2010-06-22 2016-08-23 Apellis Pharmaceuticals, Inc. Compstatin analogs for treatment of neuropathic pain
BR112012033119A2 (pt) 2010-06-22 2016-10-25 Univ Colorado Regents anticorpos para o fragamento c3d do componente do complemento 3.
TWI560199B (en) 2010-08-31 2016-12-01 Sanofi Sa Peptide or peptide complex binding to α2 integrin and methods and uses involving the same
TW201241008A (en) 2010-10-01 2012-10-16 Alexion Pharma Inc Polypeptides that bind to human complement component C5
US8865164B2 (en) 2010-11-02 2014-10-21 Kypha, Inc. Detecting complement activation
PT3156420T (pt) 2010-12-06 2019-05-27 Seattle Genetics Inc Anticorpos humanizados a liv-1 e seu uso para tratar o cancro
AU2011349049B2 (en) 2010-12-22 2016-08-11 Teva Pharmaceuticals Australia Pty Ltd Modified antibody with improved half-life
DK2694108T3 (en) 2011-04-08 2018-08-20 Univ Leicester METHODS OF TREATING DISEASES ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION
HUE049154T2 (hu) 2011-05-04 2020-09-28 Omeros Corp Készítmények a MASP-2-függõ komplement-aktiválás gátlására
US9289467B2 (en) 2011-08-10 2016-03-22 Case Western Reserve University Compositions and methods for treating bone conditions
WO2013093027A1 (en) 2011-12-22 2013-06-27 Csl Behring Gmbh Use of c1-inhibitor for the treatment of secondary edema of the central nervous system
JP6081699B2 (ja) 2011-12-28 2017-02-15 雅史 溝上 Ｉｌ−２８ｂの分析方法
KR102041412B1 (ko) 2011-12-30 2019-11-11 한미사이언스 주식회사 면역글로불린 Ｆｃ 단편 유도체
WO2014066744A2 (en) * 2012-10-25 2014-05-01 True North Therapeutics, Inc. Anti-complement c1s antibodies and uses thereof
ES2912396T3 (es) 2012-11-02 2022-05-25 Bioverativ Usa Inc Anticuerpos anti-C1s del complemento y uso de los mismos
BR112015018438A2 (pt) * 2013-01-31 2017-07-18 Seoul Nat Univ R&Db Foundation anticorpo contra c5 e método para prevenir e tratar doenças relacionadas a complemento
US20140294812A1 (en) 2013-03-15 2014-10-02 Xencor, Inc. Fc variants that improve fcrn binding and/or increase antibody half-life
EP2997045A4 (en) 2013-05-15 2016-11-23 Annexon Inc ANTI-FACTOR C1S ANTIBODIES OF THE COMPLEMENT AND USES THEREOF
US9944717B2 (en) * 2013-05-23 2018-04-17 Broteio Pharma B.V. Binding molecules that bind human complement factor C2 and uses thereof
SG11201510316UA (en) 2013-07-09 2016-01-28 Annexon Inc Anti-complement factor c1q antibodies and uses thereof
WO2015084999A1 (en) 2013-12-06 2015-06-11 True North Therapeutics, Inc. Complement component biomarker assays
US20170247460A1 (en) 2014-10-18 2017-08-31 Pfizer Inc. Anti-il-7r antibody compositions
EP4212175A1 (en) * 2015-04-06 2023-07-19 Bioverativ USA Inc. Humanized anti-c1s antibodies and methods of use thereof
HK1254030A1 (zh) 2015-06-26 2019-07-12 比奥贝拉蒂美国公司 治疗自身免疫病症和同种免疫病症的方法
IL326479A (en) 2016-10-12 2026-04-01 Bioverativ Usa Inc Anti-c1s antibodies and methods of use thereof
SG11201907583TA (en) 2017-03-14 2019-09-27 Bioverativ Usa Inc Methods for treating complement-mediated diseases and disorders
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
MX2020010528A (es) 2018-04-13 2020-11-06 Chugai Pharmaceutical Co Ltd Anticuerpos anti-componente de complemento y metodos de uso.
MX2021004356A (es) 2018-10-18 2021-05-31 Merck Sharp & Dohme Llc Formulaciones de anticuerpos anti-rsv y metodos de uso de las mismas.
BR112023001942A2 (pt) 2020-08-06 2023-02-28 Bioverativ Usa Inc Citocinas inflamatórias e fadiga em indivíduo com doença mediada por complemento
TW202304508A (zh) 2021-03-31 2023-02-01 美商百歐維拉提夫美國公司 減少冷凝集素疾病患者之手術相關溶血
IL317666A (en) 2022-06-15 2025-02-01 Bioverativ Usa Inc Anti-complement formulation for C1S antibody
MA71249A (fr) 2022-06-24 2025-04-30 Bioverativ Usa Inc. Méthodes de traitement de maladies médiées par complément

Also Published As

Publication number Publication date
JP2022105114A (ja) 2022-07-12
IL308156A (en) 2023-12-01
SI3525583T1 (sl) 2025-12-31
AR110677A1 (es) 2019-04-24
AU2025267421A1 (en) 2025-12-04
IL308156B1 (en) 2026-03-01
TWI846007B (zh) 2024-06-21
TW202434298A (zh) 2024-09-01
EP3525583B8 (en) 2025-09-10
CO2019004741A2 (es) 2019-07-31
KR102891406B1 (ko) 2025-11-27
US12391750B2 (en) 2025-08-19
ECSP19033211A (es) 2019-07-31
KR20240025715A (ko) 2024-02-27
AU2017341766A1 (en) 2019-05-23
EP3525583A1 (en) 2019-08-21
JP7069138B2 (ja) 2022-05-17
IL265957B2 (en) 2024-04-01
MY198182A (en) 2023-08-09
HRP20251304T1 (hr) 2025-12-05
PH12019500789A1 (en) 2019-07-29
CN116554320A (zh) 2023-08-08
EP3525583B1 (en) 2025-07-23
SG11201903012RA (en) 2019-05-30
PL3525583T3 (pl) 2026-01-19
US20260092104A1 (en) 2026-04-02
NZ753111A (en) 2025-06-27
MX2019004259A (es) 2019-09-27
KR102638884B1 (ko) 2024-02-22
IL265957B1 (en) 2023-12-01
ZA201902247B (en) 2024-07-31
WO2018071676A1 (en) 2018-04-19
CL2019000975A1 (es) 2019-10-04
CN110300520B (zh) 2022-10-04
BR112019007309A2 (pt) 2019-07-02
HUE073475T2 (hu) 2026-01-28
TW202246327A (zh) 2022-12-01
JP2024038319A (ja) 2024-03-19
JP2020502996A (ja) 2020-01-30
AU2022205174A1 (en) 2022-09-29
TW201821437A (zh) 2018-06-16
EP4652926A2 (en) 2025-11-26
US20240076363A1 (en) 2024-03-07
TWI773695B (zh) 2022-08-11
CN110300520A (zh) 2019-10-01
JP7420864B2 (ja) 2024-01-23
IL326479A (en) 2026-04-01
ES3049257T3 (en) 2025-12-15
TN2019000109A1 (en) 2020-10-05
DOP2019000085A (es) 2019-07-31
PE20191031A1 (es) 2019-08-05
KR20250171438A (ko) 2025-12-08
PT3525583T (pt) 2025-10-22
RS67326B1 (sr) 2025-11-28
FI3525583T3 (fi) 2025-10-31
CR20190223A (es) 2019-08-21
EP3525583A4 (en) 2020-06-10
IL265957A (en) 2019-05-30
CA3040253A1 (en) 2018-04-19
EP4652926A3 (en) 2026-03-18
IL308156B2 (en) 2026-07-01
DK3525583T3 (da) 2025-10-27
AU2022205174B2 (en) 2025-08-14
KR20190082783A (ko) 2019-07-10
US20200048332A1 (en) 2020-02-13
MX2024008202A (es) 2024-07-15
EA201990884A1 (ru) 2019-10-31

Similar Documents

Publication Publication Date Title
IL304117A (en) Anti-pvrig antibodies and methods of use
LT3601358T (lt) Anti-trem2 antikūnai ir jų naudojimo metodai
IL265800A (en) Anti-lag-3 antibodies and methods of using them
IL259747A (en) Antibodies targeting fc receptor-like 5 and methods of use
IL262095A (en) Anti-pacap antibodies and uses thereof
IL263657A (en) Anti-c5 antibodies and methods of use
IL251970B (en) Anti-cd79b antibodies and methods of use
LT3618928T (lt) Anti-sortilino antikūnai ir jų panaudojimo būdai
SG10201912879YA (en) Anti-sirp-alpha antibodies and methods of use thereof
IL267097A (en) Antigen binding proteins against neurophilin and methods of using them
SG10201912563XA (en) Anti-tim-3 antibodies and methods of use thereof
PL3353210T3 (pl) Przeciwciała anty-TIGIT i sposoby stosowania
KR20180084817A (ko) 항-siglec-9 항체 및 이의 이용 방법
IL265957A (en) Anti-c1s antibodies and methods of using them
PT3215532T (pt) Anticorpos anti-tim3 e métodos de utilização
LT3390444T (lt) Antigeną surišantys baltymai prieš tl1a ir jų panaudojimo būdai
LT3303396T (lt) Antikūnai prieš ox40 ir jų panaudojimo būdai
LT3333191T (lt) Anti-c10orf54 antikūnai ir jų panaudojimas
LT3280441T (lt) Anti-sortilino antikūnai ir jų naudojimo būdai
LT3353212T (lt) Optimizuoti anti-cd3 bispecifiniai antikūnai ir jų naudojimas
PL3250610T3 (pl) Przeciwciała anty-FcRn i sposoby ich stosowania
IL249092A0 (en) Anti-gitr antibodies and methods of use thereof
LT3274370T (lt) Antikūnai prieš ceacam6 ir jų panaudojimas
LT3532499T (lt) Antikūnai prieš il-33 ir jų panaudojimas
IL254670A0 (en) Humanized anti-c1s antibodies and methods of use thereof